Research programme: allergic diseases therapeutics - Ambicion/RIKEN

Drug Profile

Research programme: allergic diseases therapeutics - Ambicion/RIKEN

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambicion; RIKEN
  • Class Antiallergics
  • Mechanism of Action Immunosuppressants; Natural killer cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hypersensitivity

Most Recent Events

  • 13 Jul 2017 Ambicion and RIKEN agree to co-develop allergy diseases therapeutics in Japan
  • 13 Jul 2017 Early research in Hypersensitivity in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top